Agoracom Blog Home

Archive for the ‘AGORACOM Client Feature’ Category

CLIENT FEATURE: Valeo Pharma $VPH.ca $VPHIF An Innovative Canadian Pharma Company With 9 Products Currently Marketed And 7 Products In Pipeline $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 12:04 PM on Wednesday, January 13th, 2021

(VPH: CSE) (VPHIF: OTCQB) (VP2: FSE)

www.valeopharma.com

Why Valeo Pharma?

  • Commercial stage revenue generating Canadian pharmaceutical company
  • Approaching EBITDA positive in coming months
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • $1.5M in quarterly revenue ending July 31, 2020
  • $5.26M in revenue for 9 months ending July 31, 2020

What Exactly Does Valeo Pharma Do?

  • Acquires Canadian rights to commercial stage, innovative and proprietary drugs
  • Commercializes innovative prescription products in Canada
  • Focused on Neurodegenerative Diseases,  Oncology and Hospital Specialty Products
  • Internally manages portfolio through all stages of commercialization

Highlights of MDBriefCase Newsletter Comparing Hesperidin and Vitamin C for COVID-19

  • Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
  • Hesperidin may help against Covid-19 viral replication
  • Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm

Click below to read in its entirety.

Hub On AGORACOM / Corporate Profile

FULL DISCLOSURE: Valeo Pharma is an advertising client of AGORA Internet Relations Corp.

CLIENT FEATURE: Else Nutrition $BABY.ca $BABYF Backed By A $2.7 Billion Global Nutrition Powerhouse $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 4:03 PM on Tuesday, January 12th, 2021
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Else Nutrition Holdings Inc. (BABY: TSXV) (BABYF: OTCQX) (0YF: FSE) is the award winning, plant-based nutrition company for small cap investors. The shift towards plant-based alternatives has opened the food market to new players, and created an opportunity for fast growth in a rapidly expanding space.  

Highlights include:

  • $CAD 30 Million In Cash
  • Launched 1st Commercial Product Into US Market
  • Backed By A $2.7 Billion Dollar Global Nutrition Company;
  • MOU For International Distribution Of Products
  • “Best Health” Award At Global Food Innovation Summit In Milan;
  • Awarded Patents In 22 Countries, 44 Countries Pending;
  • Executives & Advisors From Globally Renowned Companies & Institutions
  • Distribution agreement with one of the largest and most well regarded national fresh, organic and specialty food distributors in North America
  • Received key Clean Label Certifications for Toddler Nutrition Product
  • Received Key USDA Organic Certification

Else Expands North American Retail Presence as first Baby Category Product on Plant X – a Leading Plant-Based Ecommerce and Digital Community

Hub On AGORACOM / Corporate Profile

Else Nutrition Holdings is an advertising client of AGORA Internet Relations Corp.

CLIENT FEATURE: Xphyto Therapeutics $XPHY.ca Providing Investor Access to Leading Edge Bioscience Opportunities $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM-Eric at 12:37 PM on Thursday, January 7th, 2021

(CSE:XPHY / OTC:XPHYF / FSE:4XT)

  • Completed Successful SARS-CoV-2 RT-PCR Diagnostic Test Kit Validation
  • Secured Exclusive Psychedelic Drug Development Agreement
  • Appointed European Healthcare Executive to Board of Director
  • Engaged German Partner for Development of Psilocybin API Production
  • Announced Update on Contract Drug Delivery Program
  • Announced Update on Oral Thin Film Drug Delivery Program
  • Provided Update on Parkinson’s Transdermal Patch

Three Xphyto Divisions:

1. Vektor Pharma TF: World-class thin film drug delivery platforms for transdermal and oral dissolvable dosage forms

2. 3a-Diagnostics: Rapid, low-cost screening tests for pandemic and dental health applications

3. Xphyto Laboratories Inc.: Development of industrial production processes for emerging active pharmaceutical ingredients, including psychedelics and cannabinoid isolates

1. Vektor Pharma TF GmbH – Drug Delivery

100% owned XPhyto subsidiary

Global leader in design, testing and manufacture of therapeutic film drug delivery systems

  • Major pharma clients – past, present and future
  • Focused and nimble team – rapid turnaround on new opportunities

Versatile platform technology

  • Transdermal patches (TDS) – slow and steady release
  • Oral dissolvable film (ODF) sublingual strips – instant bioavailability

EU GMP facilities in Baden-Württemberg, Germany

Holder of numerous German narcotics import and manufacturing licences

XPhyto Drug Development Pipeline – Stage 1 & 2

  • Platform technology
  • Scalable product development pipeline
  • High-growth and new API opportunities
  • Neurological indications
  • Generic and hybrid-generic drug formulations

2. 3a-Diagnostics GmbH – Rapid Testing

XPhyto has an exclusive development, technology purchase and licence agreement

Specializing in the development, production, and marketing of low-cost point-of-care screening test systems:

  • COVID-19 rapid PCR Kit
  • COVID-19 disposable ultra-rapid test
  • Oral biosensors for the instant detection of bacterial and viral pathogens
  • Influenza A, H1N1 (swine flu), H5N1 (avian flu), Strep A, stomatitis, periimplantitis and periodontitis
  • Biosensor screening platform for high-throughput for identification of new biosensor targets for new biosensor products

Development partially funded by grants from the German Federal Ministry of Education and Research (BMBF)

Lead Products:

COVID-19 rapid PCR Kit

  • Diagnostic level accuracy, rapid results (<25 minutes), minimal lab equipment
  • European commercial approval and product launch planned for Q1 2021

Periimplantitis oral biosensor

  • For the early detection of infection associated with dental implants
  • Biosensor releases an extremely bitter compound when exposed to the causative pathogenic bacteria
  • European commercial approval and product launch planned for Q4 2021 

3. XPhyto Laboratories Inc. & Vektor Pharma TF GmbH – Psychedelics

100% owned XPhyto subsidiaries

Exclusive agreements with leading German and Canadian universities

Germany:

  • Development of psychedelic drug formulations – sublingual and transdermal
  • Development of biotechnology process for industrial scale production of psilocybin API
  • 12-month development program commenced Q3 2020

Canada:

  • Certified analytical testing for cannabis and psychedelics
  • Development programs for industrial scale and EU GMP production of mescaline, MDMA, DMT, and cannabinoid isolates
  • Novel psychedelic drug formulations

Clinical validation planned for Germany and Canada

Hub On AGORACOM / Corporate Profile

CLIENT FEATURE: Valeo Pharma $VPH.ca $VPHIF An Innovative Canadian Pharma Company With 9 Products Currently Marketed And 7 Products In Pipeline $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 1:56 PM on Thursday, December 31st, 2020

(VPH: CSE) (VPHIF: OTCQB) (VP2: FSE)

www.valeopharma.com

Why Valeo Pharma?

  • Commercial stage revenue generating Canadian pharmaceutical company
  • Approaching EBITDA positive in coming months
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • $1.5M in quarterly revenue ending July 31, 2020
  • $5.26M in revenue for 9 months ending July 31, 2020

What Exactly Does Valeo Pharma Do?

  • Acquires Canadian rights to commercial stage, innovative and proprietary drugs
  • Commercializes innovative prescription products in Canada
  • Focused on Neurodegenerative Diseases,  Oncology and Hospital Specialty Products
  • Internally manages portfolio through all stages of commercialization

Watch Our Recent Interview:

Hub On AGORACOM / Corporate Profile

FULL DISCLOSURE: Valeo Pharma is an advertising client of AGORA Internet Relations Corp.

CLIENT FEATURE: Universal #PropTech $UPI.ca Delivering Healthy Building Solutions and Services For Building Developers, Owners and Operators #AI #IoT $SNE $MSFT $HON

Posted by AGORACOM-JC at 9:43 AM on Wednesday, December 23rd, 2020

UPI: TSX-V

www.universalproptech.com

As the name implies “PropTech” is a combination of two words and stands for “property technology.”  As simple as that is, the implementation and importance of PropTech is anything but. 

Like every other industry on the planet that is incorporating technology to create greater efficiencies and experiences, the commercial real estate market is no different and is seeing the rapid adoption of;

  • Artificial Intelligence
  • Machine learning
  • Big data
  • Internet of Things (IoT Sensors)
  • Cloud computing

To create cost savings by reducing and even eliminating existing costs, create greater efficiencies for the operation and maintenance of real estate assets, as well as, improve the design of new builds.

IMPACT OF COVID-19

The COVID-19 pandemic has served to significantly increased the demand for PropTech in the commercial real estate market as follows:

  • The need for solutions to get workers back into workplace buildings and offices. Specifically, the need to identify bacteria and viruses in indoor air quality, as well as, the ability to sanitize immediately and effectively.
  • The need to create even greater cost savings and efficiencies for real estate owners that will continue suffering losses until workers significantly return to the workplace.

WHY UNIVERSAL PROPTECH (UPI:TSXV)?

Whereas many companies are just now trying to capitalize on the opportunities presented in the current and massive future of PropTech, Universal PropTech Inc. (“UPI”) a diversified investment platform delivering healthy building solutions and services for building developers, owners and operators in Canada.  More than just lip service, UPI has been successfully delivering its PropTech solutions for years, with revenues over the last 3 years as follows:

2017 – $13.8M

2018 – $13.7M

2019 – $15.9M

Headquartered in Toronto, UPI has offices across Canada including Halifax,Montreal, and Ottawa. 

COMPANY HIGHLIGHTS

  • Used in Federal Government facilities for over 40 years
  • Provides real estate managers turnkey HVAC Building Controls design, equipment, installation and ongoing operations and maintenance services for Industrial, Commercial, Institutional and Multi-residential customers
  • Already possesses under-utilized IP in building controls to add in additional monitoring inputs and equipment controls
  • Diverse revenue streams via products, installations and ongoing
  • Key strategic partnerships afford the ability to monitor real-time utility meters, key BAS and systems data in a building.
  • Team has the capability to make sense of this data and apply advanced web tools to make recommendations to fine tune a building, saving from 5% to 15% of a facilities energy spend without capital expenditure
  • VCI offers the depth and breadth of Building Automation Systems (BAS) knowledge and products from the likes of Siemens and Honeywell to support building automation systems

RECENT NEWS

COVID-19 STRATEGY

As businesses return to the office, property managers must think about the design and safety of their buildings for occupants. Traditional cleaning methods are ineffective at preventing transmission. UV technology is able to sanitize all surfaces free from pathogens. UPI is capitalizing on this opportunity by building and acquiring UV technology as it is the best in the market to administer and integrate it into healthy buildings in Canada.

FIND OUT MORE:

Hub On AGORACOM / Corporate Profile

CLIENT FEATURE: Innocan Pharma $INNO.ca Developing The Pharmaceutical Guided Missile To Defeat Coronavirus Lung Infections $CGC.ca TLRY $VFF.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 11:38 AM on Tuesday, December 15th, 2020
Innocan-Blog

Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids. 

3 Fully Operating Divisions For Investor Diversification

Innocan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

PHARMACEUTICAL – THE GUIDED MISSILE – Revolutionary technology targeting lungs infected with coronavirus or other viral infections.

CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.

Global Manufacturing / Distribution Agreements

  • Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
  • Swiss CBD provider Cloud 9 Switzerland LLC (Distribution – Italy and Switzerland)
  • Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)
  • iAmHealth Distribution UG (Distribution – Germany)

Completed Trademark Registration in the EU, UK and Switzerland

  • Completion of the registration of its trademarks: Innocan Pharma, Relief & Go and SHIR in the EU, UK and Switzerland.
  • These trademarks represent Innocan’s OTC and derma cosmetic brand products that were recently launched in the German and UK markets.

Superior Management Team

In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself.  The InnoCan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:

  • Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
  • Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
  • Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
  • Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.

Together they have built one of the most formidable teams in the small cap cannabis world

Hub On AGORACOM / Corporate Profile

CLIENT FEATURE: Fabled Silver Gold Corp. $FCO.ca 3.2Moz Indicated and 1.1Moz Inferred at Santa Maria, Mexico $GGD.ca $EDR.ca $RDU.ca $KTN.ca

Posted by AGORACOM-Eric at 4:32 PM on Monday, December 14th, 2020

Fabled Silver Gold Corp. (TSXV: FCO)The Santa María Property is an under-explored, high-grade silver-gold project with significant exploration potential to expand mineral resources and identify new discoveries.

Fabled Silver Gold Company Highlights:

  • Commenced drilling on 100% option at Santa Maria Mine in Mexico 
  • 2020 NI 43-101 Resource of 3.2Moz Indicated and 1.1Moz Inferred in two primary veins
  • Two distinct Epithermal veins have been partially explored
  • Santa María Property is an under-explored, high-grade silver-gold project with significant exploration potential
    • 19 significant vein structures exists within the property and provides future virgin exploration opportunities
    • Drill Hole SM18-03 – Intersected 11.2m of 1,672 g/t Silver & 3.74g/t Gold
      • Hole ended in mineralization
  • Geophysical survey on the property and has successfully identified multiple targets for exploration and drilling

Santa Maria Deposit

High Grade silver-gold property located in mining friendly jurisdiction of Parrall, Mexico

  • The Parral mining district is situated in the center of the Mexican Silver belt, a district of epithermal silver gold mineralization
  • The belt has been recognized as producing more silver than any other equivalent are in the world 
  • 2018 PEA very supportive at current market prices 
  • 2 Mettalurgical Studies completed 
  • Santa Maria vein structures provide many promising exploration and possibly future mining possibilities 
  • The Santa Maria mine has never been systematically, or explored thoroughly with modern methods

The Asset: Santa Maria Mine 43-101

  • 3.2Moz Indicated and 1.1Moz Inferred in two primary veins
  1. High grade silver-gold property located in the mining friendly jurisdiction of Parrall, Chihuahua, Mexico.
  2. The Parral mining district is situated in the centre of the Mexican silver belt epithermal silver-gold vein districts. The belt has been recognized as a significant metallogenic province, which has reportedly produced more silver than any other equivalent area in the world.
  3. 43-101 Technical Report completed on December 02, 2020 by Mineral Resources Engineering.
  4. Significant vein structures within the property provides future exploration and mining opportunities.

Hub On AGORACOM / Corporate Profile

Fabled Silver Gold is an advertising client of AGORA Internet Relations Corp.

CLIENT FEATURE: Else Nutrition $BABY.ca $BABYF Backed By A $2.7 Billion Dollar Global Nutrition Powerhouse $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 12:09 PM on Monday, December 14th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Else Nutrition Holdings Inc. (BABY: TSXV) (BABYF: OTCQX) (0YF: FSE) is the award winning, plant-based nutrition company for small cap investors. The shift towards plant-based alternatives has opened the food market to new players, and created an opportunity for fast growth in a rapidly expanding space.  Else has fully grasped at this opportunity as seen below.

Highlights include:

  • $CAD 30 Million In Cash
  • Launched 1st Commercial Product Into US Market
  • Backed By A $2.7 Billion Dollar Global Nutrition Company;
  • MOU For International Distribution Of Products
  • “Best Health” Award At Global Food Innovation Summit In Milan;
  • Awarded Patents In 22 Countries, 44 Countries Pending;
  • Executives & Advisors From Globally Renowned Companies & Institutions
  • Distribution agreement with one of the largest and most well regarded national fresh, organic and specialty food distributors in North America
  • Received key Clean Label Certifications for Toddler Nutrition Product
  • Received Key USDA Organic Certification

Else Nutrition’s Complete Nutrition for Toddlers ranked Top-Selling Product on Amazon’s Hot New Releases in Baby and Toddler Formula Category 

Hub On AGORACOM / Corporate Profile

Else Nutrition Holdings is an advertising client of AGORA Internet Relations Corp.

CLIENT FEATURE: Hollister Biosciences $HOLL.ca $HSTRF Hits All-Time High, Wholly Owned Subsidiary Venom Extracts Achieves $40 Million Revenue Milestone $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 3:38 PM on Friday, December 11th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Hollister Biosciences Inc. (HOLL:CSE) (HSTRF:OTC) (HOB: FRANKFURT) is a multi-state cannabis company with products in 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, translating into the following great success: 

REVENUES  $CAD 

  • Q1  $1,200,000
  • Q2  $11,500,000
  • Q3  $12,500,000

NOTE: Venom Extracts Acquisition Closed at the end of Q1.

TOTAL Q1/Q2/Q3

  • REVENUE  $25.2M

On December 9 th, 2020, Venom achieved the second and final revenue milestone by generating in excess of CDN$40,000,000 of revenue calculated from January 1 st, 2020.

With the recent passage of Proposition 207 – legalizing the cultivation, sale and consumption of recreational cannabis in the state of Arizona Hollister is extremely well positioned to capitalize. This can best be summed up by quote of Venom Extracts Founder below:

“Seeing recreational Cannabis legalized in the state is an encouraging sign and is hopefully another step toward federal legalization. It should lead to increased tax revenue and job creation. The recreational cannabis market in Arizona could be valued at up to US $760 million by 2024 1 , significantly expanding the total addressable market for Cannabis in the state. We look forward to making our product line available to both the medical and recreational end user.” Shared Jacob Cohen, Founder of Venom Extracts, Hollister’s 100% owned subsidiary based in Arizona

In addition to organic sales, Hollister has several high-level partnerships that demonstrate how trusted the Company is within the industry, including:

Hub On AGORACOM / Corporate Profile

CLIENT FEATURE: Avicanna $AVCN.ca $AVCNF A Revenue Generating, Canadian Vertically – Integrated Biopharmaceutical Company $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 3:12 PM on Friday, December 11th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Avicanna (AVCN: TSX) (AVCN: OTCQX) (0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.

Third Quarter Highlights

  • $882K in revenue, an increase of 24% from Q2-2020,
  • Double-digit growth, quarter over quarter from Q4-2019
  • In addition, the Company was able to reach a major milestone with the launch of certain products from its RHO Phyto product line in Canada and further diversified its revenue streams.

When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:

1.  The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year. 

2.  Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain.

Recently Launched Medical Cannabis Program with its RHO Phyto™ Formulary Nationwide in Colombia (Read More)

Leveraging the successful launch of the Company’s RHO Phyto branded advanced medical cannabis product line in Canada, the portfolio of preparations, including oil drops, sublingual sprays, capsules and topicals, are now available nationwide in Colombia through physician prescription.

  • The medical program includes Avicanna’s 3 pillars aimed at setting the gold standard for medical cannabis in Colombia and other Latin American markets, including
    • Medical community education,
    • Advanced pharmaceutical grade cannabinoid preparations,
    • Comprehensive patient support program

3.  Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.

AND… if that is not enough …

4.  Avicanna’s Colombian cultivation division hosts 500,000 Sq ft of low cost and USDA certified organic Cannabis Cultivation. The company recently Made History As The First Ever Export Of Feminized Hemp Seeds From Colombia To The United States. 7,000,000 Seeds For $380,000, with an additional 75,000,000 Seeds Available For Export In Several Pending Transactions.

Hub On AGORACOM / Corporate Profile